Company: PRME
Filing Date: 2025-11-07
Form Type: S-3ASR
Source: 0001628280-25-050428
Chunk: 75

Company: Prime Medicine, Inc.
Filing Date: 2025-11-07
Form: S-3ASR
Chunk 75
---
 our board of directors, to our officers and certain employees, in connection with legal proceedings relating to their service for or on behalf of us, subject to limited exceptions.

We have entered into indemnification agreements with each of our directors and executive officers.

These agreements provide that we will indemnify each of our directors, our executive officers and, at times, their affiliates to the fullest extent permitted by Delaware law. We will advance expenses, including attorneys’ fees (but excluding judgments, fines and settlement amounts), to each indemnified director, executive officer or affiliate in connection with any proceeding in which indemnification is available and we will indemnify our directors and officers for any action or proceeding arising out of that person’s services as a director or officer brought on behalf of us or in furtherance of our rights. Additionally, certain of our directors or officers may have certain rights to indemnification, advancement of expenses or insurance provided by their affiliates or other third parties, which indemnification relates to and might apply to the same proceedings arising out of such director’s or officer’s services as a director referenced herein. Nonetheless, we have agreed in the indemnification agreements that our obligations to those same directors or officers are primary and any obligation of such affiliates or other third parties to advance expenses or to provide indemnification for the expenses or liabilities incurred by those directors are secondary.

We also maintain general liability insurance which covers certain liabilities of our directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers, including liabilities under the Securities Act.

<div align='center'>II-2</div>

## Item 16. Exhibits and Financial Statement Schedules.
(a) Exhibits

| Exhibit No. 
 1.1*        
 1.2**       
 3.1         |     | Description                                                                                                                                                                                                                                                                                   
 Form of Underwriting Agreement                                                                                                                                                                                                                                                                
 Open Market Sales AgreementSM, dated as of November 3, 2023, between the Registrant and Jefferies LLC                                                                                                                                                                                         
 Third Amended and Restated Certificate of Incorporation of Prime Medicine, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed with the SEC on October 24, 2022)                                                                             |
|:------------|:----|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 3.2         |     | Certificate of Amendment to Third Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.